Clinical Impact of Preemptive Pharmacogenomic Testing on Antiplatelet Therapy in a Real-World Setting

Medicine, Infectious Diseases, Medical Laboratory Science, Neurology, Pharmacy, Cardiovascular System, Life Sciences, Immunology, Genetics,
pharmacogenomics   antiplatelet therapy   CYP2C19   acute coronary syndromes   percutaneous coronary interventions   clinical outcomes   healthcare utilization  

Clinical Impact of Pharmacogenomic Testing on Antiplatelet Therapy Background Pharmacogenomics (PGx) is changing the use of P2Y12 inhibitors (antiplatelet drugs), which are widely used in the treatment of acute coronary syndrome (ACS), neurovascular problems, and vascular diseases. Among them, clopidogrel is a commonly used P2Y12 inhibitor. This pr...